{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:04:12Z","timestamp":1780639452461,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Metabolic dysfunction is increasingly recognized as a pivotal factor in cognitive decline and neurodegenerative diseases, such as Alzheimer\u2019s disease (AD). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), notably the long-acting agonist semaglutide, exhibit significant metabolic efficacy and pronounced neuroprotective effects across a broad spectrum of preclinical models. This is corroborated by extensive epidemiological studies that consistently link GLP-1RA use with a decreased incidence of dementia. Nevertheless, promising preclinical and observational findings have not been mirrored in clinical success for the treatment of established AD. Recent negative outcomes from the pivotal phase 3 EVOKE and EVOKE+ trials, which demonstrated no clinical benefit of oral semaglutide in patients with early AD, have resulted in a notable translational paradox. This review critically examines the mechanistic, preclinical, epidemiological, and clinical evidence concerning the impact of semaglutide on cognitive function to reconcile these conflicting findings. Preclinical studies have revealed complex neuroprotective mechanisms, including suppression of neuroinflammation, restoration of metabolic function, and activation of pro-survival pathways. Conversely, clinical trials in symptomatic AD have been unsuccessful, although modest and clinically insignificant changes in cerebrospinal fluid biomarker levels have been observed. We propose the hypothesis that the current body of evidence is consistent with a prevention-focused model, wherein semaglutide\u2019s primary value may lie in modifying the upstream metabolic and inflammatory drivers of neurodegeneration, such as those prevalent in vascular and metabolic cognitive impairment, rather than reversing established amyloid-driven AD pathology. This hypothesis, however, remains speculative and requires prospective validation in appropriately designed trials. This review seeks to resolve the apparent contradictions in the literature and propose future research directions centered on appropriate patient populations and therapeutic windows.<\/jats:p>","DOI":"10.3389\/fnagi.2026.1851072","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:36:48Z","timestamp":1780637808000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework"],"prefix":"10.3389","volume":"18","author":[{"given":"Ahmad H.","family":"Alhowail","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University","place":["Buraydah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz K.","family":"Al Mouslem","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University","place":["Al Ahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Almatrafi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University","place":["Buraydah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha A.","family":"Aldubayan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University","place":["Buraydah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e194745","DOI":"10.1172\/jci194745","article-title":"The promise of GLP-1 receptor agonists for neurodegenerative diseases.","volume":"136","author":"Athauda","year":"2026","journal-title":"J. Clin. Investig."},{"key":"B2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/cid\/ciaf577","article-title":"Effects of semaglutide on cognitive function in people with human immunodeficiency virus: A randomized, controlled trial.","volume":"82","author":"Atieh","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.medj.2025.100916","article-title":"Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial.","volume":"7","author":"Badulescu","year":"2026","journal-title":"Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10557-019-06915-8","article-title":"Neuroprotection in rats following ischaemia-reperfusion injury by GLP-1 analogues\u2014Liraglutide and semaglutide.","volume":"33","author":"Basalay","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jocn.2020.09.054","article-title":"Semaglutide-mediated protection against A\u03b2 correlated with enhancement of autophagy and inhibition of apotosis.","volume":"81","author":"Chang","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"975830","DOI":"10.3389\/fphar.2023.975830","article-title":"Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice.","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13098-024-01497-4","article-title":"Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.","volume":"16","author":"Chen","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.14283\/jpad.2022.41","article-title":"Clinical trial endpoints and their clinical meaningfulness in early stages of Alzheimer\u2019s disease.","volume":"9","author":"Cohen","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.","volume":"4","author":"Cork","year":"2015","journal-title":"Mol. Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2024-335593","article-title":"Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders.","volume":"96","author":"De Giorgi","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/193229680800200619","article-title":"Alzheimer\u2019s disease is type 3 diabetes\u2014Evidence reviewed.","volume":"2","author":"de la Monte","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: First global approval.","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e17891","DOI":"10.7717\/peerj.17891","article-title":"Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice.","volume":"12","author":"Feng","year":"2024","journal-title":"PeerJ"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.molmet.2024.102019","article-title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice.","volume":"89","author":"Forny Germano","year":"2024","journal-title":"Mol. Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2876156","DOI":"10.1155\/ije\/2876156","article-title":"Unveiling tirzepatide\u2019s therapeutic spectrum: A dual GIP\/GLP-1 agonist targeting metabolic, neurological, and cardiovascular health.","volume":"2025","author":"Ghaleb","year":"2025","journal-title":"Int. J. Endocrinol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/cne.24905","article-title":"A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain.","volume":"528","author":"Graham","year":"2020","journal-title":"J. Comp. Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/13872877251319054","article-title":"Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis.","volume":"104","author":"Hui","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"123688","DOI":"10.1016\/j.jchromb.2023.123688","article-title":"Novel LC-MS\/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats.","volume":"1221","author":"Lee","year":"2023","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2521016","DOI":"10.1001\/jamanetworkopen.2025.21016","article-title":"Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity.","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: An update on pathobiology and treatment strategies.","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e12268","DOI":"10.1002\/trc2.12268","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e00712","DOI":"10.1016\/j.neurot.2025.e00712","article-title":"From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics.","volume":"22","author":"Roy","year":"2025","journal-title":"Neurotherapeutics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"109647","DOI":"10.1016\/j.intimp.2022.109647","article-title":"Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway.","volume":"115","author":"Sadek","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics.","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1002\/alz.14346","article-title":"Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer\u2019s disease pathophysiology.","volume":"20","author":"Schauer","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e70200","DOI":"10.1002\/trc2.70200","article-title":"Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer\u2019s disease.","volume":"12","author":"Scheltens","year":"2026","journal-title":"Alzheimers Dement."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease.","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"100805","DOI":"10.1016\/j.medj.2025.100805","article-title":"The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity.","volume":"6","author":"Scragg","year":"2025","journal-title":"Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.14336\/ad.2021.1029","article-title":"Blocking C3d+\/GFAP+ A1 astrocyte conversion with semaglutide attenuates blood-brain barrier disruption in mice after ischemic stroke.","volume":"13","author":"Tang","year":"2022","journal-title":"Aging Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease.","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.3390\/ijms25094972","article-title":"A systematic review of semaglutide\u2019s influence on cognitive function in preclinical animal models and cell-line studies.","volume":"25","author":"Tipa","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3892\/ijmm.2021.5052","article-title":"Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole-kindled mice.","volume":"48","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement."},{"key":"B35","doi-asserted-by":"publisher","first-page":"45057","DOI":"10.1038\/s41598-025-30756-1","article-title":"Vascular risk factor variability and cognitive impairment in older adults a community-based retrospective study.","volume":"15","author":"Wang","year":"2025","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"109716","DOI":"10.1016\/j.neuropharm.2023.109716","article-title":"Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer\u2019s disease via the GLP-1R\/SIRT1\/GLUT4 pathway.","volume":"240","author":"Wang","year":"2023","journal-title":"Neuropharmacology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/13872877251329439","article-title":"Semaglutide improves cognitive function and neuroinflammation in APP\/PS1 transgenic mice by activating AMPK and inhibiting TLR4\/NF-\u03baB pathway.","volume":"105","author":"Zhai","year":"2025","journal-title":"J. Alzheimers Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson\u2019s disease mouse model.","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"B39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/jpd-181503","article-title":"Semaglutide is neuroprotective and reduces \u03b1-synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease.","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Parkinsons Dis."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1851072\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:36:49Z","timestamp":1780637809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1851072\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":39,"alternative-id":["10.3389\/fnagi.2026.1851072"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1851072","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1851072"}}